Document Detail

Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.
MedLine Citation:
PMID:  16845254     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Fibrates were reported to be effective in reducing recurrent coronary events in coronary heart disease patients with elevated triglycerides. It is not known whether this effect is related to the extent of triglyceride reduction.
METHODS: Participants comprised 3090 coronary heart disease patients enrolled in the Bezafibrate Infarction Prevention study, which showed a nonsignificant reduction (9.4%; P=0.26) in fatal or nonfatal myocardial infarction and sudden death during a mean follow-up time of 6.2 years.
RESULTS: Significant reduction in triglyceride serum level was evident only among patients allocated to bezafibrate, ranging between 0.06 mmol/l (5 mg/dl) in the lowest decile of baseline triglycerides level and 0.68 mmol/l (60 mg/dl) in the highest baseline decile. The extent of triglyceride reduction with bezafibrate was significantly associated with the reduction of risk; relative risk reduction of 55% (hazards ratio: 0.45; 95% confidence interval: 0.24-0.84) was observed among patients with baseline triglycerides>or=2.26 mmol/l who reduced triglyceride level to >0.50 mmol/l (>44.3 mg/dl). In contrast, the risk of recurrent events among patients treated with bezafibrate and achieving less triglyceride reduction or failing to reduce triglyceride level was not significantly different from that of patients treated with placebo.
CONCLUSION: Bezafibrate treatment was associated with significant risk reduction among coronary heart disease patients with elevated triglyceride levels that substantially reduced their triglyceride level with treatment.
Moti Haim; Michal Benderly; Valentina Boyko; Ilan Goldenberg; David Tanne; Alex Battler; Uri Goldbourt; Solomon Behar;
Related Documents :
2203244 - Clinical trials including an update on the helsinki heart study.
19728844 - Taqib polymorphism in cholesterol ester transfer protein (cetp) gene predicts future ca...
20071874 - The significance of lipid profile and positive troponin in predicting cardiac event.
11256844 - Statin therapy: where are we? where do we go next?
1246954 - Risk of death related to coronary arteriography: role of left coronary arterial lesions.
3829484 - Bidirectional flow in congenital ventricular septal defect: a doppler echocardiographic...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Coronary artery disease     Volume:  17     ISSN:  0954-6928     ISO Abbreviation:  Coron. Artery Dis.     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-07-17     Completed Date:  2006-11-28     Revised Date:  2013-02-07    
Medline Journal Info:
Nlm Unique ID:  9011445     Medline TA:  Coron Artery Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  455-61     Citation Subset:  IM    
Cardiology Department, Rabin Medical Center, Petach-Tikva, Sackler School of Medicine, Tel-Aviv University, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bezafibrate / pharmacology*,  therapeutic use
Clofibric Acid / pharmacology*,  therapeutic use
Hypertriglyceridemia / drug therapy*
Hypolipidemic Agents / pharmacology*,  therapeutic use
Middle Aged
Prospective Studies
Recurrence / prevention & control*
Risk Assessment
Risk Factors
Triglycerides / blood*
Reg. No./Substance:
0/Hypolipidemic Agents; 0/Triglycerides; 41859-67-0/Bezafibrate; 882-09-7/Clofibric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hemodynamic responses and long-term follow-up results in patients using chronic beta 1-selective and...
Next Document:  Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarc...